Sanofi’s Tzield accepted for priority review in the US for young children with stage 2 type 1 diabetes If approved, Tzield would be the first disease-modifying therapy to delay the onset of stage 3 T1D in children aged one and older diagnosed with stage 2 T1DTzield slows disease progression by protecting the insulin-secreting beta cells of the pancreasThe priority review is based on interim results from the PETITE-T1D phase 4 study Paris, January 5, 2026. The US Food and Drug Administration (FDA) has accept ...